POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada
Abstract
Authors
A Amadi K Toor E Keeney H Thom P Singh I Kim E Mameri